Related references
Note: Only part of the references are listed.Use of Biosimilar Medications in Oncology
Zeina Nahleh et al.
JCO ONCOLOGY PRACTICE (2022)
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update
Neelima Denduluri et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim
Mariana P. Socal et al.
VALUE IN HEALTH (2020)
Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage
Pinar Karaca-Mandic et al.
HEALTH AFFAIRS (2019)
Rationale, Opportunities, and Reality of Biosimilar Medications
Gary H. Lyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Financial Toxicity in Adults With Cancer: Adverse Outcomes and Noncompliance
Thomas G. Knight et al.
JOURNAL OF ONCOLOGY PRACTICE (2018)